Sandy Balkin - Royalty Pharma Senior Analytics
| RPRX Stock | USD 26.60 0.31 1.18% |
Executive
Sandy Balkin is Senior Analytics of Royalty Pharma Plc
| Address | 110 East 59th Street, New York, NY, United States, 10022 |
| Phone | 212 883 0200 |
| Web | https://www.royaltypharma.com |
Royalty Pharma Management Efficiency
The company has return on total asset (ROA) of 0.0569 % which means that it generated a profit of $0.0569 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1728 %, meaning that it created $0.1728 on every $100 dollars invested by stockholders. Royalty Pharma's management efficiency ratios could be used to measure how well Royalty Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.09 in 2024. Return On Capital Employed is likely to rise to 0.11 in 2024. At this time, Royalty Pharma's Total Assets are fairly stable compared to the past year. Other Assets is likely to rise to about 16.3 B in 2024, whereas Intangible Assets are likely to drop slightly above 1.7 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Mark Underwood | Madrigal Pharmaceuticals | N/A | |
| AxelSven Malkomes | CureVac NV | 57 | |
| Patrick Lamy | Akero Therapeutics | 51 | |
| Karen Lewis | Apellis Pharmaceuticals | 51 | |
| Jeffrey Eisele | Apellis Pharmaceuticals | 62 | |
| Caroline MD | Apellis Pharmaceuticals | 57 | |
| Kevin Smyth | Iovance Biotherapeutics | N/A | |
| Keith White | Amylyx Pharmaceuticals | N/A | |
| Karina Calzadilla | Adaptive Biotechnologies Corp | N/A | |
| Robert Sweeney | Ocean Biomedical | 59 | |
| Catriona Yale | Akero Therapeutics | 52 | |
| Myriam MD | CureVac NV | 58 | |
| Joaquim Marques | Ginkgo Bioworks Holdings | N/A | |
| Ariel Hurley | Blueprint Medicines Corp | 50 | |
| Bob Lally | Ikena Oncology | N/A | |
| Liza Heapes | BeiGene | N/A | |
| Patrick Baumhof | CureVac NV | N/A | |
| Debra DursoBumpus | Blueprint Medicines Corp | 54 | |
| David MS | Ikena Oncology | N/A | |
| Samantha Vuksanic | Ikena Oncology | N/A | |
| Susan Bobulsky | Adaptive Biotechnologies Corp | 43 | |
Management Performance
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.0569 |
Royalty Pharma Plc Leadership Team
Elected by the shareholders, the Royalty Pharma's board of directors comprises two types of representatives: Royalty Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Royalty. The board's role is to monitor Royalty Pharma's management team and ensure that shareholders' interests are well served. Royalty Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Royalty Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eric Schneider, Senior Officer | ||
| George Lloyd, Executive Officer | ||
| Marshall MD, Executive Investments | ||
| Sandy Balkin, Senior Analytics | ||
| Sara Klymkowsky, Senior Investments | ||
| Terrance Coyne, Executive CFO | ||
| Ashwin MD, Executive Investments | ||
| Kristin Stafford, Senior Officer | ||
| Arthur JD, Executive Counsel | ||
| James Reddoch, Executive Officer | ||
| Molly Sawaya, Executive Capital | ||
| Sean Weisberg, VP Counsel | ||
| CPA CFA, Senior Communications | ||
| Alessandra Sassun, Senior Capital | ||
| Pablo Legorreta, Chairman Founder | ||
| Christopher Hite, Vice VP |
Royalty Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Royalty Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.0569 | ||||
| Profit Margin | 0.51 % | ||||
| Operating Margin | 1.30 % | ||||
| Current Valuation | 17.66 B | ||||
| Shares Outstanding | 444.3 M | ||||
| Shares Owned By Insiders | 13.16 % | ||||
| Shares Owned By Institutions | 72.77 % | ||||
| Number Of Shares Shorted | 14.67 M | ||||
| Price To Earning | 37.70 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.